Limited in vivo production of type i or type III interferon after infection of macaques with vaccine or wild-type strains of measles virus

Journal of Interferon and Cytokine Research

Volumn 35, Issue 4, 2015, Pages 292-301

  Shivakoti, Rupak ^a,b   Hauer, Debra ^a   Adams, Robert J ^b   Lin, Wen Hsuan W ^a,e   Duprex, William Paul ^c   De Swart, Rik L ^d   Griffin, Diane E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON STIMULATED GENE FACTOR 56; INTERLEUKIN 28B; MEASLES VACCINE; MESSENGER RNA; MX1 PROTEIN; NUCLEIC ACID BINDING PROTEIN; TRANSCRIPTION FACTOR; TYPE II INTERFERON; TYPE III INTERFERON; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INNATE IMMUNITY; MACAQUE MODEL; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS STRAIN; WILD TYPE; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; IMMUNOLOGY; MACACA; POLYMERASE CHAIN REACTION; VERO CELL LINE;

MACACA; MEASLES VIRUS;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; IMMUNITY, INNATE; INTERFERON TYPE I; INTERFERONS; MACACA; MEASLES VIRUS; POLYMERASE CHAIN REACTION; VERO CELLS;

EID: 84926452181     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0122     Document Type: Article

References (47)

1. Alammar L, Gama L, Clements JE. 2011. Simian immunodeficiency virus infection in the brain and lung leads to differential type I IFN signaling during acute infection. J Immunol 186(7):4008-4018.
2. Auwaerter PG, Rota PA, Elkins WR, Adams RJ, DeLozier T, Shi Y, Bellini WJ, Murphy BR, Griffin DE. 1999. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis 180(4):950-958.
3. Calain P, Curran J, Kolakofsky D, Roux L. 1992. Molecular cloning of natural paramyxovirus copy-back defective interfering RNAs and their expression from DNA. Virology 191:62-71.
4. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uzé G. 2004. Viral infection and toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34(3):796-805.
5. De Swart RL, Ludlow M, De Witte L, Yanagi Y, Van Amerongen G, McQuaid S. Yuksel S, Geijtenbeek TBH, Duprex WP, Osterhaus ADME. 2007. Predominant infection of CD150 + lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 3(11):e178.
6. Devaux P, Hodge G, McChesney MB, Cattaneo R. 2008. Attenuation of V-or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol 82(11):5359-5367.
7. Devaux P, Hudacek AW, Hodge G, Reyes-del Valle J, McChesney MB and Cattaneo R. 2011. A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. J Virol 85:348-356.
8. De Vries RD, Lemon K, Ludlow M, McQuaid S, Yüksel S, van Amerongen G, Rennick LJ, Rima BK, Osterhaus ADME, de Swart RL, Duprex WP. 2010. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol 84(9):4714-4724.
9. De Vries RD, McQuaid S, van Amerongen G, Yuksel S, Verburgh RJ, Osterhaus ADME, Duprex WP, de Swart RL. 2012. Measles immune suppression: Lessons from the macaque model. PLoS Pathog 8:e1002885.
10. El Mubarak HS, Yüksel S, van Amerongen G, Mulder PGH, Mukhtar MM, Osterhaus ADME, de Swart RL. 2007. Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type measles viruses. J Gen Virol 88:2028-2034.
11. Enders J, Peebles T. 1954. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 86(2):277-286.
12. Fireman P, Friday G, Kumate J. 1969. Effect of measles vaccine on immunologic responsiveness. Pediatrics 43(2):264-272.
13. Fontana JM, Bankamp B, Bellini WJ, Rota PA. 2008. Regulation of interferon signaling by the C and V proteins from attenuated and wild-type strains of measles virus. Virology 374(1):71-81.
14. Forthal DN, Aarnaes S, Blanding J, de la Maza L, Tilles JG. 1992. Degree and length of viremia in adults with measles. J Infect Dis 166(2):421-424.
15. Griffin DE. 2010. Measles virus-induced suppression of immune responses. Immunol Rev 236:176-189.
16. Hashimoto K, Ono N, Tatsuo H, Minagawa H, Takeda M, Takeuchi K, Yanagi Y. 2002. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein. J Virol 76:6743-6749.
17. Ito M, Iwasaki M, Takeda M, Nakamura T, Yanagi Y, Ohno S. 2013. Measles virus nonstructural C protein modulates viral RNA polymerase activity by interacting with host protein SHCBP1. J Virol 87:9633-9642.
18. Kessler JR, Kremer JR, Muller CP. 2011. Interplay of measles virus with early induced cytokines reveals different wild type phenotypes. Virus Res 155(1):195-202.
19. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
20. Lemon K, de Vries RD, Mesman AW, McQuaid S, van Amerongen G, Yüksel S, Ludlow M, Rennick LJ, Kuiken T, Rima BK, Geijtenbeek TBH, Osterhaus ADME, Duprex WP, de Swart RL. 2011. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog 7(1):e1001263.
21. Lin WH, Griffin DE, Rota PA, Papania M, Cape SP, Bennett D, Quinn B, Sievers RE, Shermer C, Powell K, Adams RJ, Godin S, Winston S. 2011. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci U S A 108(7):2987-2992.
22. Lin WHW, Kouyos RD, Adams RJ, Grenfell BT, Griffin DE. 2012. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A 109(37):14989-14994.
23. Monafo WJ, Haslam DB, Roberts RL, Zaki SR, Bellini WJ, Coffin CM. 1994. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 124(2):273-276.
24. Naniche D, Yeh A, Eto D, Manchester M, Friedman RM, Oldstone MB. 2000. Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of alpha/beta interferon production. J Virol 74(16):7478-7484.
25. Oldstone MBA. 2006. Viral persistence: parameters, mechanisms and future predictions. Virology 344(1):111-118.
26. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. 2001. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 75(9):4399-4401.
27. Pan C, Valsamakis A, Colella T, Nair N, Adams RJ, Polack FP, Greer CE, Perri S, Polo JM, Griffin DE. 2005. Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 102(33):1581-11588.
28. Parisien JP, Bamming D, Komuro A, Ramachandran A, Rodriguez JJ, Barber G, Wojahn RD, Horvath CM. 2009. A shared interface mediates paramyxovirus interference with antiviral RNA helicases MDA5 and LGP2. J Virol 83(14):7252-7260.
29. Parks GD, Alexander-Miller MA. 2013. Paramyxovirus activation and inhibition of innate immune responses. J Mol Biol 425:4872-4892.
30. Perry RT, Gacic-Dobo M, Dabbagh A, Mulders MN, Strebel PM, Okwo-Bele JM, Rota PA, Goodson JL. 2014. Global control and regional elimination of measles, 2000-2012. MWR Morb Mortal Wkly Rep 63:103-107.
31. Pfaller CK, Conzelmann KK. 2008. Measles virus V protein is a decoy substrate for IkappaB kinase alpha and prevents tolllike receptor 7/9-mediated interferon induction. J Virol 82(24):12365-12373.
32. Rota JS, Hummel KB, Rota PA, Bellini WJ. 1992. Genetic variability of the glycoprotein genes of current wild-type measles isolates. Virology 188(1):135-142.
33. Rota JS, Wang ZD, Rota PA, Bellini WJ. 1994. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 31:317-330.
34. Sakaguchi M, Yoshikawa Y, Yamanouchi K, Sata T, Nagashima K, Takeda K. 1986. Growth of measles virus in epithelial and lymphoid tissues of cynomolgus monkeys. Microbiol Immunol 30(10):1067-1073.
35. Sarkar SN, Sen GC. 2004. Novel functions of proteins encoded by viral stress-inducible genes. Pharm Ther 103(3):245-259.
36. Sato H, Kobune F, Ami Y, Yoneda M, Kai C. 2008. Immune responses against measles virus in cynomolgus monkeys. Comp Immunol Microbiol Infect Dis 31(1):25-35.
37. Seya T. 2011. Addendum to "Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-binducing potential" [Mol. Immunol. 48(4) (2011) 497-504]. Mol Immunol 48(12-13):1589-1590.
38. ShingaiM, Ebihara T, Begum NA, Kato A, Honma T,Matsumoto K, Saito H, Ogura H, Matsumoto M, Seya T. 2007. Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J Immunol 179(9):6123-6133.
39. Shivakoti R, Siwek M, Hauer D, Schultz KLW, Griffin DE. 2013. Induction of dendritic cell production of type I and type III interferons by wild-type and vaccine strains of measles virus: role of defective interfering RNAs. J Virol 87:7816-7827.
40. Smaron MF, Saxon E, Wood L, McCarthy C, Morello JA. 1991. Diagnosis of measles by fluorescent antibody and culture of nasopharyngeal secretions. J Virol Methods 33(1-2):223-229.
41. Stetson DB, Medzhitov R. 2006. Type I interferons in host defense. Immunity 25(3):373-381.
42. Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140(6):805-820.
43. Tamashiro VG, Perez HH, Griffin DE. 1987. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr Infect Dis J 6(5):451-454.
44. Van Binnendijk RS, van der Heijden RW, van Amerongen G, UytdeHaag FG, Osterhaus AD. 1994. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis 170(2):443-448.
45. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS. 2007. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369(9557):191-200.
46. World Health Organization. 1998. Expanded Programme on Immunization (EPI). Standardization of the nomenclature for describing the genetic characteristics of wild-type measles viruses. Wkly Epidemiol Rec 73(35):265-269.
47. Zilliox MJ, Moss WJ, Griffin DE. 2007. Gene expression changes in peripheral blood mononuclear cells during measles virus infection. Clin Vaccine Immunol 14(7):918-923.